Pregabalin (Pregabalin Ivax, Pregabalin Pch, Nurika)
Pregabalin
Teva Pharmaceuticals (Pty) Ltd
Registration
- Applicant
- Teva Pharmaceuticals (Pty) Ltd
- Certificate holder
- Teva Pharmaceuticals (Pty) Ltd
- Registrations
- 12
- Schedule source
- SAHPRA documentation
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pregabalin ivax 25 EACH CAPSULE CONTAINS PREGABALIN 25,0 mg | 25/50/75/150 mgCapsules | 46076446/2.5/0764Approved 14 April 2025 | Registered | S5 | PIPIL |
| Pregabalin ivax 50 EACH CAPSULE CONTAINS PREGABALIN 50,0 mg | 25/50/75/150 mgCapsules | 46076546/2.5/0765Approved 14 April 2025 | Registered | S5 | PIPIL |
| Pregabalin ivax 75 EACH CAPSULE CONTAINS PREGABALIN 75,0 mg | 25/50/75/150 mgCapsules | 46076646/2.5/0766Approved 14 April 2025 | Registered | S5 | PIPIL |
| Pregabalin ivax 150 EACH CAPSULE CONTAINS PREGABALIN 150,0 mg | 25/50/75/150 mgCapsules | 46076746/2.5/0767Approved 14 April 2025 | Registered | S5 | PIPIL |
| Pregabalin pch 25 EACH CAPSULE CONTAINS PREGABALIN 25,0 mg | 25/50/75/150 mgCapsule | 460768.76446/2.5/0768.764Approved 8 June 2023 | Cancelled | S5 | PIPIL |
| Pregabalin pch 50 EACH CAPSULE CONTAINS PREGABALIN 50,0 mg | 25/50/75/150 mgCapsule | 460769.76546/2.5/0769.765Approved 8 June 2023 | Cancelled | S5 | PIPIL |
| Pregabalin pch 75 EACH CAPSULE CONTAINS PREGABALIN 75,0 mg | 25/50/75/150 mgCapsule | 460770.76646/2.5/0770.766Approved 8 June 2023 | Cancelled | S5 | PIPIL |
| Pregabalin pch 150 EACH CAPSULE CONTAINS PREGABALIN 150,0 mg | 25/50/75/150 mgCapsule | 460771.76746/2.5/0771.767Approved 8 June 2023 | Cancelled | S5 | PIPIL |
| Nurika 25 EACH CAPSULE CONTAINS PREGABALIN 25,0 mg | 25Capsule | 460772.76446/2.5/0772.764Approved 14 April 2025 | Registered | S5 | PIPIL |
| Nurika 50 EACH CAPSULE CONTAINS PREGABALIN 50,0 mg | 50Capsule | 460773.76546/2.5/0773.765Approved 14 April 2025 | Registered | S5 | PIPIL |
| Nurika 75 EACH CAPSULE CONTAINS PREGABALIN 75,0 mg | 75Capsule | 460774.76646/2.5/0774.766Approved 14 April 2025 | Registered | S5 | PIPIL |
| Nurika 150 EACH CAPSULE CONTAINS PREGABALIN 150,0 mg | 150Capsule | 460775.76746/2.5/0775.767Approved 14 April 2025 | Registered | S5 | PIPIL |
Regulatory status
Where S5 sits on the scale
Prescription-only, with tighter controls on repeats.
Schedule 5 medicines need a prescription, and repeat dispensing is capped at six months in total; the prescriber must state upfront how many times, and at what intervals, it may be repeated. Extra limits apply to some uses: if it is being used for its anxiolytic, antidepressant, tranquillising or analgesic properties, it cannot be prescribed for longer than six months without a further consultation. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S5, read from the product's PI-PIL leaflet.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it.
Consolidated Schedules listings for Pregabalin
S5: Pregabalin
Consolidated Schedules 06 July 2026, line 9660
Pharmacological class: Anticonvulsants, including anti-epileptics. (class 2.5)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(3S)-3-(Aminomethyl)-5-methylhexanoic acid
Drag to rotate. Structure from PubChem CID 5486971.
SAHPRA documents
Schedule Verification
This medication's schedule (S5) has been verified from official SAHPRA documents with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.